An observational study in Juvenile Idiopathic Arthritis and Non-infectious Uveitis, sponsored by Meyer Children's Hospital IRCCS. Recruiting at 1 site in Italy. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Meyer Children's Hospital IRCCS · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Arthritis, Juvenile with a site in Italy — 20 open to participants now, 25 under way, 11 of them phase 3. Arthritis, Juvenile · Italy.
Among the 57 studies in Arthritis, Juvenile with a site in Italy, this one is the 12th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2026, is one of 14 observational ones, reaches primary completion later than 23 of the 24 other live ones, and was the 57th registered.
367 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.
Browse Arthritis, Juvenile studies →20 of the 57 studies in Arthritis, Juvenile with a site in Italy are open now. Recruiting first, the newest first:
Alfasigma S.p.A. · Sites in Italy, Belgium, Czechia and 6 more countries
Ages 8–18
Duke University · Sites in Italy, United States, Germany and 1 more country
Ages 2–21
Novartis Pharmaceuticals · Sites in Italy, United States, Canada and 5 more countries
Ages 1+
Bristol-Myers Squibb · Sites in Italy, United States, Brazil and 8 more countries
Ages 5–17
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 6–18
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 28 · Phase 4 2
First in 2000; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 120 across 119 observational studies indexed under Arthritis, Juvenile.
Median enrollment 90 across the 43 interventional studies, 115 across the 14 observational. Of the 30 that completed or were terminated, 20 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 57 have an industry lead sponsor. The 10 most frequent:
Meyer Children's Hospital IRCCS is the lead sponsor of 79 studies on the registry; 56 are open to participants now.
Meyer Children's Hospital IRCCS has 3 studies filed under Arthritis, Juvenile — fewer than ten, so there is no comparison to draw.
3 of the studies in Arthritis, Juvenile with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07554495Phase 3Alfasigma S.p.A.Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents | 2027-06 |
| NCT06618937Istituto Giannina GasliniToward Personalized Medicine to Guide Drug Withdrawal in Children with Juvenile Idiopathic Arthritis in Clinical Remission | 2027-01-01 |
| NCT07203001Novartis PharmaceuticalsA Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease | 2027-04-22 |
Add all 3 to your calendar (.ics) → With an account.
Among the 57 studies in Arthritis, Juvenile with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, single-center observational cohort study aims to investigate the development of anti-Adalimumab antibodies in pediatric patients with juvenile idiopathic arthritis (JIA) and/or chronic non-infectious uveitis initiating Adalimumab treatment.
The study will assess the frequency and timing of antibody development, identify potential predictive factors, including concomitant methotrexate treatment, and explore associations between immunogenicity, serum Adalimumab concentrations, disease activity, and clinical outcomes.
A total of 60 patients will be enrolled and followed for 24 months. Clinical data and additional blood samples will be collected at baseline and at 3, 6, 12, 18, and 24 months during routine clinical visits.
Anti-Adalimumab antibodies and serum drug concentrations will be measured using surface plasmon resonance (SPR) technology. Treatment decisions will remain entirely based on routine clinical practice.
Adalimumab is widely used in the treatment of juvenile idiopathic arthritis (JIA) and chronic non-infectious uveitis. Despite its established efficacy, some patients experience inadequate clinical response, secondary loss of efficacy, or disease flares during treatment. The development of anti-Adalimumab antibodies (AAA) may contribute to reduced serum drug concentrations and impaired therapeutic response. However, evidence regarding the incidence, timing, and clinical significance of AAA in paediatric patients remains limited and heterogeneous.
This prospective, single-centre, observational cohort study aims to investigate the development and kinetics of AAA in paediatric patients with JIA and/or chronic non-infectious uveitis initiating Adalimumab treatment. The study will also explore potential predictive factors for AAA development, including concomitant methotrexate therapy, and evaluate associations between immunogenicity, serum Adalimumab concentrations, disease activity, and clinical outcomes.
A total of 60 Adalimumab-naïve patients will be consecutively enrolled at AOU Meyer IRCCS, Florence, Italy. All participants will receive Adalimumab according to routine clinical practice, independently of study participation. No investigational treatment or study-related therapeutic intervention is planned.
Each participant will be followed for 24 months, with assessments at baseline and at 3, 6, 12, 18, and 24 months. Clinical and laboratory data will be collected during routine follow-up visits, including demographic characteristics, disease subtype and duration, concomitant treatments, disease activity measures, inflammatory markers, disease flares, and treatment modifications.
At each scheduled assessment, an additional 5 mL peripheral blood sample will be collected during routine blood sampling. Serum samples will be analysed at the PeptLab laboratory of the University of Florence using surface plasmon resonance (SPR) technology to determine AAA positivity and levels, as well as serum Adalimumab concentrations. AAA positivity will be defined according to a predefined threshold of 15 Response Units (RU).
The primary outcomes are the proportion of patients developing AAA during follow-up and the time from Adalimumab initiation to the first detection of AAA. Secondary outcomes include the identification of clinical and treatment-related factors associated with AAA development, changes in disease activity and functional assessment scores (JADAS-10 and CHAQ), inflammatory markers, occurrence and number of disease flares, and persistence of AAA positivity.
Statistical analyses will include descriptive and exploratory multivariable methods, longitudinal models for repeated measurements, and time-to-event analyses accounting for interval censoring when appropriate. Particular attention will be given to the potential association between concomitant methotrexate treatment and AAA development.
The overall study duration is expected to be 72 months, including 36 months of recruitment, individual follow-up, and final data analysis and reporting.
The study aims to improve understanding of Adalimumab immunogenicity in paediatric JIA and chronic non-infectious uveitis and to explore the potential clinical value of immunopharmacological monitoring in identifying patients at risk of secondary treatment failure or disease relapse.
Pediatric patients with juvenile idiopathic arthritis (JIA) and/or chronic non-infectious uveitis followed at the Pediatric Rheumatology Unit of AOU Meyer IRCCS, Florence, Italy, for whom initiation of Adalimumab treatment is clinically indicated.
Eligible patients must be Adalimumab-naïve and will be consecutively enrolled during routine outpatient or day-hospital visits. Treatment decisions will be made independently of study participation, according to standard clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age at diagnosis between 2 and 16 years.
Diagnosis of juvenile idiopathic arthritis (JIA) according to the International League of Associations for Rheumatology (ILAR) criteria, established on or after January 1, 2015, and/or diagnosis of chronic non-infectious uveitis according to the Standardization of Uveitis Nomenclature (SUN) Working Group criteria, established on or after January 1, 2015.
Clinical indication to initiate Adalimumab treatment in patients with no previous exposure to Adalimumab (Adalimumab-naïve), as determined by the treating physician.
Written from parents or legal guardians and assent from minors aged 7 years or older, where applicable.
Exclusion Criteria:
Age 18 years or older at enrollment.
Diagnoses other than juvenile idiopathic arthritis or chronic non-infectious uveitis.
to Adalimumab, including tuberculosis exposure, history of multiple sclerosis or other demyelinating central nervous system disorders, or history of .
Previous exposure to Adalimumab before study enrollment.
Body weight below 12 kg.
Age below 24 months at enrollment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pediatric patients diagnosed with juvenile idiopathic arthritis (JIA) and/or chronic non-infectious uveitis who are initiating Adalimumab treatment according to routine clinical practice and have not previously received Adalimumab. Patients will be prospectively followed for 24 months, with clinical assessments and blood sample collection at baseline and at 3, 6, 12, 18, and 24 months to evaluate the development of anti-Adalimumab antibodies, serum drug concentrations, and clinical outcomes.
Other: Diagnostic test
Anti-Adalimumab Antibody and Serum Drug Level Assessment by SPR
Proportion of Patients Developing Anti-Adalimumab Antibodies
Proportion of patients with detectable anti-Adalimumab antibodies (AAA) during the 24-month follow-up, assessed using surface plasmon resonance (SPR). Antibody positivity will be defined using a predefined cut-off of 15 Response Units (RU).
Time frame: Baseline and Months 3, 6, 12, 18, and 24
Time to Development of Anti-Adalimumab Antibodies
Time from initiation of Adalimumab treatment to the first detection of anti-Adalimumab antibodies, assessed at scheduled follow-up visits. The analysis will account for interval censoring between the last negative and first positive antibody determinations.
Time frame: From baseline to Month 24.
Factors Associated With Anti-Adalimumab Antibody Development
Assessment of the association between anti-Adalimumab antibody (AAA) development and demographic, clinical, and laboratory factors, including sex, age, JIA subtype according to ILAR classification, disease duration, baseline inflammatory markers, and serum Adalimumab concentrations.
Time frame: Baseline to Month 24
Association Between Concomitant Methotrexate Treatment and AAA Development
Assessment of the proportion of patients developing anti-Adalimumab antibodies according to concomitant methotrexate treatment (yes/no), including the time to antibody development where appropriate.
Time frame: Baseline to Month 24
Change in Juvenile Arthritis Disease Activity Score (JADAS-10)
Assessment of changes in disease activity using the Juvenile Arthritis Disease Activity Score (JADAS-10) during follow-up and their association with anti-Adalimumab antibody development.
Time frame: Baseline and Months 3, 6, 12, 18, and 24
Change in Childhood Health Assessment Questionnaire (CHAQ) Score
Assessment of changes in functional disability using the Childhood Health Assessment Questionnaire (CHAQ) during follow-up and their association with anti-Adalimumab antibody development.
Time frame: Baseline and Months 3, 6, 12, 18, and 24
Change in Inflammatory Markers (ESR and CRP)
Assessment of changes in erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels during follow-up and their association with anti-Adalimumab antibody development.
Time frame: Baseline and Months 3, 6, 12, 18, and 24
Proportion of Patients Experiencing at Least One Disease Flare
Proportion of patients experiencing at least one articular or ocular disease flare during the 24-month follow-up, according to the definitions established in the study protocol.
Time frame: Baseline to Month 24
Number of Disease Flares per Patient
Total number of articular and/or ocular disease flares recorded for each patient during the 24-month follow-up period.
Time frame: Baseline to Month 24
Persistence of Anti-Adalimumab Antibody Positivity
Proportion of anti-Adalimumab antibody-positive patients showing persistent antibody positivity, defined as two positive determinations performed at least six months apart.
Time frame: Baseline to Month 24
Started Oct 2026 (actual). Primary completion is estimated for Oct 2031, 59 months after the start.
Of 43 observational studies under Arthritis, Juvenile, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 186. This study's planned 59 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Meyer Children's Hospital IRCCS